Advertisement

Citations to this article

Abstract

Despite striking advances in the biomedical sciences, the flow of new drugs has slowed to a trickle, impairing therapeutic advances as well as the commercial success of drug companies. Reduced productivity in the drug industry is caused mainly by corporate policies that discourage innovation. This is compounded by various consequences of mega-mergers, the obsession for blockbuster drugs, the shift of control of research from scientists to marketers, the need for fast sales growth, and the discontinuation of development compounds for nontechnical reasons. Lessons from the past indicate that these problems can be overcome, and herein, new and improved directions for drug discovery are suggested.

Authors

Pedro Cuatrecasas

×

Total citations by year

Year: 2014 2013 2012 2011 2010 2009 2008 2007 Total
Citations: 9 7 16 9 9 15 14 10 89
Citation information

Citations to this article in year 2012 (16)

Title and authors Publication Year
Are the large pharmaceutical and biotechnology companies driving the discovery, research and development of targeted cancer therapies?
GJ Gallant
Future Medicinal Chemistry 2012
Translational research in infectious disease: current paradigms and challenges ahead
JM Fontana, E Alexander, M Salvatore
Translational Research 2012
Translational semantics and infrastructure: another search for the emperor's new clothes?
K Mullane, M Williams
Drug Discovery Today 2012
Absorptive, innovative and adaptive capabilities and their impact on project and project portfolio performance
T Biedenbach, R Müller
International Journal of Project Management 2012
Combination Drug Therapy for Pain following Chronic Spinal Cord Injury
A Hama, J Sagen
Pain Research and Treatment 2012
Editors' note to Raz and Eldor's commentary “Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms”. Diabetes Metab Res Rev 2012
J Roth, P Pozzilli
Diabetes/Metabolism Research and Reviews 2012
Introduction: Drug Discovery in Difficult Times
M Maccoss
Case Studies in Modern Drug Discovery and Development Huang/Case Studies Drug Discovery 2012
Pharmacogenetics and Individualized Therapy: Maitland-van der Zee/Pharmacogenetics
B Sobrino, A Carracedo
Pharmacogenetics and Individualized Therapy: Maitland-van der Zee/Pharmacogenetics 2012
A virtual high-throughput screening approach to the discovery of novel inhibitors of the bacterial leucine transporter, LeuT
KJ Simmons, K Gotfryd, CB Billesbølle, CJ Loland, U Gether, CW Fishwick, AP Johnson
Molecular Membrane Biology 2012
UK Biobank: Consequences for commons and innovation
F Huzair, T Papaioannou
Science and Public Policy 2012
Rethinking leadership in drug discovery projects
A Schneider, Z Erden, H Widmer, G Koch, C Billy, G Krogh
Drug Discovery Today 2012
Cell biology: A key driver of therapeutic innovation
O Hantschel, G Superti-Furga
The Journal of Cell Biology 2012
Drug Repurposing: Far Beyond New Targets for Old Drugs
TI Oprea, J Mestres
The AAPS Journal 2012
Translational research: the changing landscape of drug discovery
CS Fishburn
Drug Discovery Today 2012
Simulating the drug discovery pipeline: a Monte Carlo approach
MJ Yu
Journal of cheminformatics 2012
The Valley of Death in anticancer drug development: a re-assessment
DJ Adams
Trends in Pharmacological Sciences 2012

Advertisement
Advertisement